Protalix Biotherapeutics, INC Form 4 insider transactions

Protalix BioTherapeutics' President and CEO, Dror Bashan, acquired 56,000 shares of common stock at $1.81 per share, increasing his direct beneficial ownership.

Protalix BioTherapeutics Director Amos Bar-Shalev sold 168 shares of common stock at $1.87 per share under a Rule 10b5-1 plan.

Protalix BioTherapeutics Director Gwen A. Melincoff received an award of 7,500 restricted common shares and 15,000 stock options.

Protalix BioTherapeutics Director Eliot Forster acquired 7,500 restricted common shares and 15,000 stock options.

Protalix BioTherapeutics director Pol F. Boudes received 7,500 restricted shares and 15,000 stock options as equity compensation.

Aharon Schwartz, a director at Protalix BioTherapeutics, Inc., acquired 7,500 restricted common shares and 15,000 stock options on September 3, 2025.

Protalix BioTherapeutics Director Christian Elze was awarded 7,500 restricted common shares and 15,000 stock options under the company's incentive plan.

Protalix BioTherapeutics director Shmuel Ben Zvi received an award of 7,500 restricted common shares and 15,000 stock options.

Protalix BioTherapeutics Director Amos Bar-Shalev reported the acquisition of 7,500 restricted common shares and 15,000 stock options.

Protalix BioTherapeutics' Senior VP of Operations, Yaron Naos, was granted 25,000 restricted shares and options for 50,000 shares of common stock.

Protalix BioTherapeutics' President and CEO, Dror Bashan, was granted 195,000 restricted shares and options to purchase 340,000 common shares.

Aharon Schwartz, a Director at Protalix BioTherapeutics, Inc., acquired 129,000 shares of common stock at a weighted average price of $1.596 per share.

Eyal Rubin, CFO of Protalix BioTherapeutics, files an amended SEC Form 4 to correct a previously reported amount of restricted shares granted.

Eyal Rubin, CFO of Protalix BioTherapeutics, reports acquiring 99,010 shares of common stock on September 23, 2024, bringing his total beneficial ownership to 669,010 shares held indirectly through a trust.

Yaron Naos, Sr. VP of Operations at Protalix BioTherapeutics, acquired stock options for 100,000 shares at an exercise price of $1.10, vesting quarterly over three years.

Protalix BioTherapeutics' CEO, Dror Bashan, reports acquiring 263,960 shares of common stock on April 1, 2024, and beneficially owning 2,149,418 shares indirectly through a trust.